维普期刊资源整合服务平台（V6.5）

维普中文期刊产品整合服务

6篇 您的检索式：作者名="Siu Tim Cheung"

选中清除导出查看参考文献查看引证文献引用追踪共1页首页上一页第1页下一页末页 /1 跳转

		题名	作者	年代	出处	被引量
	1	Anterior Approach Versus Conventional Approach Right Hepatic Resection for Large Hepatocellular Carcinoma: A Prospective Randomized Controlled Study显示文摘	Chi Leung Liu Sheung Tat Fan Siu Tim Cheung Chung Mau Lo Irene O. Ng John Wong	2006	Annals of Surgery2006，，2：	2
	2	Claudin -10 ex- pression level is associated with recurrence of primary hepatocellular carci- noma 显示文摘	Siu Tim Cheung Ka Ling Leung Ying Chi Ip	2005	Clin Cancer Res2005，11，21：	1
	3	Inhibition of hepa- toeellular carcinoma invasion by suppression of claudin - 10 in HLE cells 显示文摘	Ying Chi Ip Siu Tim Cheung Yuk Ting Lee	2007	Mol Cancer Ther2007，6，11：	1
	4	Clinical significance of thrombospondin 1 expression in hepatocellular carcinoma 显示文摘	Poon RT Ka Kit Chung Siu Tim Cheung	2004	Clin Cancer Res2004，10，：	1
	5	Anterior Approach Versus Conventional Approach Right Hepatic Resection for Large Hepatocellular Carcinoma: A Prospective Randomized Controlled Study显示文摘	Chi Leung Liu Sheung Tat Fan Siu Tim Cheung Chung Mau Lo Irene O. Ng John Wong	2006	Annals of Surgery2006，，2：	1
	6	Novel biomarkers GEP/ABCB5 regulate response to adjuvant transarterial chemoembolization after curative hepatectomy for hepatocellular carcinoma显示文摘Background: Transarterial chemoembolization(TACE) is the most commonly used adjuvant therapy for hepatocellular carcinoma(HCC) after curative resection. Responses to TACE are variable due to tumor and patient heterogeneity. We had previously demonstrated that expression of Granulin-epithelin precursor(GEP) and ATP-dependent binding cassette(ABC)B5 in liver cancer stem cells was associated with chemoresistance. The present study aimed to evaluate the association between GEP/ABCB5 expression and response to adjuvant TACE after curative resection for HCC. Methods: Patients received adjuvant TACE after curative resection for HCC and patients received curative resection alone were identified from a prospectively collected database. Clinical samples were retrieved for biomarker analysis. Patients were categorized into 3 risk groups according to their GEP/ABCB5 status for survival analysis: low(GEP-/ABCB5-), intermediate(either GEP +/ABCB5-or GEP-/ABCB5 +) and high(GEP +/ABCB5 +). Early recurrence(recurrence within 2 years after resection) and disease-free survival were analyzed. Results: Clinical samples from 44 patients who had followed-up for more than 2 years were retrieved for further biomarker analysis. Among them, 18 received adjuvant TACE and 26 received surgery alone. Patients with adjuvant TACE in the intermediate risk group was associated with significantly better overall survival and 2-year disease-free survival than those who had surgery alone( P = 0.036 and P = 0.011, respectively). Adjuvant TACE did not offer any significant differences in the early recurrence rate, 2-year disease-free survival and overall survival for patients in low and high risk groups. Conclusions: Adjuvant TACE can only provide survival benefits for patients in the intermediate risk group(either GEP +/ABCB5-or GEP-/ABCB5 +). A larger clinical study is warranted to confirm its role in patient selection for adjuvant TACE.	Charing Ching-Ning Chong Siu Tim Cheung Yue-Sun Cheung Anthony Wing-Hung Chan Stephen Lam Chan Simon Chun-Ho Yu Paul Bo-San Lai	2018	Hepatobiliary & Pancreatic Diseases International2018，17，6：	0

返回顶部每页显示：

共1页首页上一页第1页下一页末页 /1 跳转

goolge学术搜索-维普

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费